Compare Biogen Inc (BIIB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Biogen IncTrade

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Recursion Pharmaceuticals Inc — how do they compare? Biogen Inc trades at $191.4 (market cap $30.86B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.75B). The key difference: Biogen Inc is far larger — about 17.6× Recursion Pharmaceuticals Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

	BIIB	RXRX
Market Cap	$30.86B	$1.75B
Sector	Health	Health
52-Week High	$216.63	$6.79
52-Week Low	$122.68	$2.84
Enterprise Value	$33.14B	$1.17B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BIIB

Real-world study shows 83% of early Alzheimer's patients stable or improved on LEQEMBI over 17 monthsPRNewsWire · 19 hours agoBullish Biogen's diranersen shows promising Phase 2 results slowing early Alzheimer's decline and reducing tau protein.GlobeNewsWire · 21 hours agoBullish FDA approves LEQEMBI IQLIK, first at-home weekly injection for early Alzheimer's treatmentPRNewsWire · 1 day agoBullish View details →

RXRX

Generative AI in drug discovery market to reach $0.86B by 2030, growing at 27% CAGR driven by faster drug development and AI advancesResearchandmarkets.Com · 4 days agoBullish View details →

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.